<DOC>
	<DOCNO>NCT00936377</DOCNO>
	<brief_summary>This study design evaluate dexmedetomidine adjunctive therapy severe alcohol withdrawal medical ICU patient . Specifically , study ass whether adjunctive dexmedetomidine reduces dose conventional agent use alcohol withdrawal maintain patient comfort safety explore dexmedetomidine exhibit dose-dependent profile action use indication . In addition , study assess relationship alcohol withdrawal , therapy dexmedetomidine , potential serum biomarkers alcohol withdrawal .</brief_summary>
	<brief_title>Dexmedetomidine Adjunctive Therapy Alcohol Withdrawal</brief_title>
	<detailed_description>The objective randomize , double-blind , placebo control , dose escalation study ) determine add dexmedetomidine symptom-triggered , standard therapy severe alcohol withdrawal reduces dose requirement conventional sedative , analgesic , neuroleptic ; maintain patient comfort safety ; prevents shorten tracheal intubation ; b ) explore whether dexmedetomidine act dose-dependent manner reduce dose requirement conventional sedative , analgesic , neuroleptic maintain patient comfort ; c ) determine association alcohol withdrawal potential serum biomarkers alcohol withdrawal ass whether express differently dexmedetomidine use adjunctive therapy . Dexmedetomidine add exist sedative therapy effort decrease use agent maintain patient comfort . The study randomize twenty-four patient double-blind manner receive placebo dexmedetomidine dose 0.4 1.2 µg/kg per hour maximum duration five day . All patient manage use exist institution-specific , symptom-triggered alcohol withdrawal protocol .</detailed_description>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>1 . Severe alcohol withdrawal define CIWA score ≥ 15 need least 16 mg lorazepam fourhour period . All lorazepam dos , whether oral intravenous , contribute cumulative amount . 2 . Patients receive standard therapy severe alcohol withdrawal accord symptomtriggered alcohol withdrawal protocol . Lorazepam prefer benzodiazepine agent patient require ICU admission due alcohol withdrawal . 3 . Informed consent within 36 hour qualify study . 1 . Patients &lt; 18 year age &gt; 85 year age . 2 . Patients receive benzodiazepine therapy purpose alcohol withdrawal ( e.g . sedation ) . 3 . Patients alcohol withdrawal require ICU admission . 4 . Patients receive epidural administration medication ( ) . 5 . Comatose patient metabolic neurologic affectation . 6 . Patients active myocardial ischemia second thirddegree heart block . 7 . Moribund state plan withdrawal life support . 8 . Patients know suspect severe adverse reaction dexmedetomidine ( clonidine ) . 9 . Pregnant female female suspect pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>